Evidence map›Paper›PMID 41276472›Full record

ReviewJournal of Zhejiang University. Science. B2025

Food-derived bioactive peptides: health benefits, structure‒activity relationships, and translational prospects.

Hongda Chen, Jiabei Sun, Haolie Fang, Yuanyuan Lin, Han Wu, Dongqiang Lin, Zhijian Yang, Quan Zhou, Bingxiang Zhao, Tianhua Zhou and 3 more

Abstract readReview
In one paragraph

Review in Journal of Zhejiang University. Science. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hongda ChenDepartment of Pharmacology, School of Medicine, Zhejiang University, Hangzhou 310058, China.
Jiabei SunChina National Institutes for Food and Drug Control, Beijing 102629, China.
Haolie FangDepartment of Pharmacology, School of Medicine, Zhejiang University, Hangzhou 310058, China.
Yuanyuan LinInnovation Center of Yangtze River Delta, Zhejiang University, Jiaxing 314100, China.
Han WuDepartment of Pharmacology, School of Medicine, Zhejiang University, Hangzhou 310058, China.
Dongqiang LinKey Laboratory of Biomass Chemical Engineering of Ministry of Education, College of Chemical and Biological Engineering, Zhejiang University, Hangzhou 310058, China.
Zhijian YangOcean Research Center of Zhoushan, Zhejiang University, Zhoushan 316021, China.
Quan ZhouDepartment of Cell Biology, School of Medicine, Zhejiang University, Hangzhou 310058, China.
Bingxiang ZhaoChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd., Shenzhen 518110, China.
Tianhua ZhouDepartment of Cell Biology, School of Medicine, Zhejiang University, Hangzhou 310058, China.
Jianping WuDepartment of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta 100027, Canada.
Shanshan LiCollege of Animal Sciences, Zhejiang University, Hangzhou 310058, China. lishanshan@zju.edu.cn.
Xiangrui LiuDepartment of Pharmacology, School of Medicine, Zhejiang University, Hangzhou 310058, China. xiangrui@zju.edu.cn.

Funding

the Chinese Nutrition Society (CNS) Nutrition Science Foundation‒Sino Nutri-food Oligopeptide Nutrition Research Fund CNS-FF2019A22the National Natural Science Foundation of China 52173141 and 82102192
6 · The paper itself

Abstract

Food-derived bioactive peptides (FBPs), particularly those with ten or fewer amino acid residues and a molecular weight below 1300 Da, have gained increasing attention for their safe, diverse structures and specific biological activities. The development of FBP-based functional foods and potential medications depends on understanding their structure‒activity relationships (SARs), stability, and bioavailability properties. In this review, we provide an in-depth overview of the roles of FBPs in treating various diseases, including Alzheimer's disease, hypertension, type 2 diabetes mellitus, liver diseases, and inflammatory bowel diseases, based on the literature from July 2017 to Mar. 2023. Subsequently, attention is directed toward elucidating the associations between the bioactivities and structural characteristics (e.g., molecular weight and the presence of specific amino acids within sequences and compositions) of FBPs. We also discuss in silico approaches for FBP screening and their limitations. Finally, we summarize recent advancements in formulation techniques to improve the bioavailability of FBPs in the food industry, thereby contributing to healthcare applications.

Indexed as

Functional FoodPeptidesAlzheimer DiseaseBioactive Peptides, DietaryBiological AvailabilityDiabetes Mellitus, Type 2HumansHypertensionInflammatory Bowel DiseasesLiver DiseasesStructure-Activity RelationshipBioactive Peptides, DietaryPeptidesAbsorptionBioavailabilityBiological compoundFunctional foodsIn silico predictionOral delivery

Identifiers

PMID41276472
PMCPMC12640749

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.